1. Home
  2. CPRX vs ENOV Comparison

CPRX vs ENOV Comparison

Compare CPRX & ENOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPRX
  • ENOV
  • Stock Information
  • Founded
  • CPRX 2002
  • ENOV 1995
  • Country
  • CPRX United States
  • ENOV United States
  • Employees
  • CPRX N/A
  • ENOV N/A
  • Industry
  • CPRX Biotechnology: Pharmaceutical Preparations
  • ENOV Fluid Controls
  • Sector
  • CPRX Health Care
  • ENOV Industrials
  • Exchange
  • CPRX Nasdaq
  • ENOV Nasdaq
  • Market Cap
  • CPRX 2.6B
  • ENOV 2.1B
  • IPO Year
  • CPRX 2006
  • ENOV 2008
  • Fundamental
  • Price
  • CPRX $24.69
  • ENOV $37.62
  • Analyst Decision
  • CPRX Strong Buy
  • ENOV Buy
  • Analyst Count
  • CPRX 8
  • ENOV 4
  • Target Price
  • CPRX $32.50
  • ENOV $58.50
  • AVG Volume (30 Days)
  • CPRX 1.5M
  • ENOV 931.0K
  • Earning Date
  • CPRX 05-07-2025
  • ENOV 05-01-2025
  • Dividend Yield
  • CPRX N/A
  • ENOV N/A
  • EPS Growth
  • CPRX 107.94
  • ENOV N/A
  • EPS
  • CPRX 1.31
  • ENOV N/A
  • Revenue
  • CPRX $491,734,000.00
  • ENOV $2,107,623,000.00
  • Revenue This Year
  • CPRX $15.17
  • ENOV $7.09
  • Revenue Next Year
  • CPRX $8.28
  • ENOV $6.38
  • P/E Ratio
  • CPRX $18.96
  • ENOV N/A
  • Revenue Growth
  • CPRX 23.49
  • ENOV 23.45
  • 52 Week Low
  • CPRX $14.47
  • ENOV $35.14
  • 52 Week High
  • CPRX $26.16
  • ENOV $62.79
  • Technical
  • Relative Strength Index (RSI)
  • CPRX 62.78
  • ENOV 42.34
  • Support Level
  • CPRX $20.68
  • ENOV $38.51
  • Resistance Level
  • CPRX $26.16
  • ENOV $40.70
  • Average True Range (ATR)
  • CPRX 0.83
  • ENOV 1.29
  • MACD
  • CPRX 0.36
  • ENOV 0.34
  • Stochastic Oscillator
  • CPRX 75.21
  • ENOV 50.47

About CPRX Catalyst Pharmaceuticals Inc.

Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing, developing therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome.

About ENOV Enovis Corporation

Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.

Share on Social Networks: